KHP Ventures

52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

PocDoc is a digital health platform that specializes in the development of applications for the monitoring and testing of cardiovascular, metabolic, and renal diseases. The company's innovative platform integrates a smartphone app with a physical test chip, allowing users to obtain real-time analysis of lifestyle diseases. By measuring several key biomarkers from a single drop of blood, PocDoc enables individuals to gain comprehensive insights into their health. This approach not only facilitates full health assessments but also offers follow-on care pathways, empowering users to take control of their physical well-being.

iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

deepc GmbH, based in Munich, Germany, specializes in artificial intelligence software for medical imaging, particularly in the field of radiology. The company has developed a disease-agnostic AI solution that screens medical imaging data in real-time, identifying healthy and non-healthy cases to prevent diagnostic errors. Its innovative web-based platform serves as a comprehensive operating system for diagnostics, allowing medical professionals and AI developers to seamlessly integrate diagnostic AI and other digital tools into clinical workflows. By enhancing the quality of diagnoses and improving cost-efficiency, deepc aims to facilitate immediate access to accurate diagnostics for individuals worldwide. The company has received recognition for its contributions to healthcare, including awards from the Federal Ministry for Economic Affairs and Energy.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Albus Health is a startup originating from the University of Oxford, focusing on the development of an intelligent nocturnal monitoring platform for personalized home health monitoring. The platform enables passive, contactless, and objective tracking of various symptoms and environmental metrics. This innovative system is designed primarily for use in clinical trials by leading pharmaceutical companies, facilitating the monitoring of nocturnal symptoms and aiding in the prediction of respiratory emergencies. By providing detailed insights into patient conditions, Albus Health's technology supports pharmaceutical firms in optimizing their clinical studies while enhancing revenue potential.

Machine Medicine Technologies Ltd, established in 2017 and based in London, UK, specializes in developing artificial intelligence-driven solutions for healthcare. The company's core product, KELVIN-PD, employs computer vision and pose estimation to objectively measure and analyze movement disorders, such as tremors and bradykinesia, in Parkinson's disease patients using simple video clips. This platform offers secure data management, accessibility from various devices, and affordability, making it a valuable tool for researchers and clinicians.

Phare Health operates an AI platform that automates the extraction of patient care data from unstructured clinical notes, transforming it into structured data for administrative, operational, and financial teams. This enables healthcare systems to enhance resource management, improve cost recovery, and ensure accurate reimbursement, thereby increasing efficiency and resilience in healthcare operations.

Hypervision Surgical is a company focused on enhancing surgical precision, safety, and efficiency through advanced imaging technology. It has developed a non-contact and non-invasive optical imaging system that utilizes hyperspectral imaging to analyze tissue in real-time. By splitting light into multiple spectral bands, the system enables clinicians to visualize and characterize tissues during surgery without the need for contrast agents, thereby reducing patient risk. This AI-powered solution facilitates advanced computer-assisted tissue analysis, equipping surgeons with critical data that supports informed decision-making during procedures. Hypervision Surgical aims to transform the landscape of surgery by guiding clinicians with innovative imaging solutions that prioritize patient safety and operational effectiveness.

Apian develops and provides an API and platforms that integrate drones into healthcare, connecting the healthcare sector with the drone industry to improve patient outcomes. It designs medical drones and related software to enable smarter, faster, and greener healthcare logistics in a scalable and sustainable way. The offerings support a range of electric drone platforms, including long-range fixed-wing hybrid VTOL and multi-rotor systems, to meet diverse needs and enhance medical deliveries, contributing to improved patient outcomes and staff well-being.

MediShout Ltd. is a technology company based in London, United Kingdom, that develops a digital platform aimed at enhancing operational efficiency within healthcare environments. Founded in 2013, the company addresses inefficiencies in hospitals, general practices, and care homes by connecting healthcare teams, suppliers, and logistics through its cloud-based solution. MediShout's platform integrates various systems, enabling real-time communication and collaboration among staff and departments. With features such as instant feedback, two-way conversations, and artificial intelligence for predictive analysis, MediShout empowers healthcare providers to improve care delivery, streamline operations, and ultimately focus more on patient care.

TympaHealth has created an innovative ear and hearing health assessment system, designed to enhance the capabilities of non-specialist healthcare providers. The Tympa system allows users to conduct high-definition digital otoscopy, perform microsuction wax removal, and conduct hearing screenings all within a single 30-minute appointment. Additionally, the platform enables the secure upload of patient images and videos to the cloud, facilitating remote evaluation by ENT specialists globally. This approach not only improves accessibility to ear and hearing health services but also supports allied healthcare professionals in delivering timely and effective diagnoses and consultations.

52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

Feebris Ltd is a UK-based company, founded in 2017 and headquartered in Saffron Walden, that specializes in developing artificial intelligence and machine learning algorithms for the detection of respiratory conditions. The company creates a mobile software platform that integrates with various point-of-care devices, such as digital stethoscopes and wearables. This technology is designed for community-based diagnosis and monitoring, allowing non-clinical users to identify early signs of deterioration in patients, thereby preventing complications and reducing the need for hospitalization. Feebris' team comprises experts in biomedical engineering, machine learning, global health, and business, all dedicated to transforming healthcare into a more equitable, personalized, and patient-driven system.

iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

WeWALK is a London‑based company that develops a smart cane to enhance mobility for visually impaired individuals. The cane incorporates an ultrasonic sensor that detects obstacles above chest level and delivers haptic alerts, allowing users to navigate safely. It is paired with a mobile application that offers outdoor navigation, way‑finding, and integration with public transportation data. Additional features include voice control via Amazon Alexa and customizable settings. Founded in 2017, WeWALK applies artificial intelligence and user‑centric design to create a safer, more independent experience for people with visual impairments.

Acurable is a London-based MedTech company that develops wearable sensor-based devices for at‑home diagnosis and management of respiratory conditions. Its flagship AcuPebble captures internal body sounds using non-invasive sensors and transmits data to a mobile device, where algorithms extract clinical parameters and biomarkers relevant to sleep apnea. The system enables remote assessments by patients and healthcare providers, supporting home monitoring without hospital visits and facilitating more accessible, cost-effective care. Founded in 2016, Acurable emphasizes research-driven development to advance at‑home respiratory care.

Apian develops and provides an API and platforms that integrate drones into healthcare, connecting the healthcare sector with the drone industry to improve patient outcomes. It designs medical drones and related software to enable smarter, faster, and greener healthcare logistics in a scalable and sustainable way. The offerings support a range of electric drone platforms, including long-range fixed-wing hybrid VTOL and multi-rotor systems, to meet diverse needs and enhance medical deliveries, contributing to improved patient outcomes and staff well-being.

Doccla provides virtual ward services that move care from hospital to home through remote monitoring. A tech-agnostic partner to care organisations, it enables early discharge and reduces hospital readmissions by remotely monitoring patients with devices. Services include at-home onboarding with monitoring equipment, supported by a mobile team of nurses and doctors who conduct ongoing monitoring and manage offboarding as patients recover, delivering higher quality care at lower cost. The Covid-19 support service originated from NHS research and is deployed in collaboration with Northampton General Hospital.

Patchwork Health, founded in 2016 by NHS doctors Anas Nader and Jing Ouyang, offers a digital workforce platform that connects healthcare workers directly with local staff banks. The system matches vacant shifts with a growing marketplace of clinicians, improving temporary staffing fill rates and patient safety while reducing costs for the NHS. By streamlining the recruitment process, it enhances the experience for both workers and patients, ensuring that qualified staff are available when needed.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.